Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hyperglycemia × volagidemab × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1 Breast 1

Conditions

Hyperglycemia 1 Hereditary Sensory and Autonomic Neuropathies 1 Breast Neoplasms 1

Interventions

Alpelisib 3 Fulvestrant 2 volagidemab 1 exemestane 1 dapagliflozin 1 Vildagliptin 1 Tamoxifen 1 Metformin 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04330625 2022-11-08

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Duke University

Phase 1 Terminated

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡